Diabetes drugs linked to slower frailty progression in older adults
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2)…
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
If approved, investigational semaglutide 7.2 mg injection would offer the optionality of a higher dose for greater weight…
Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials | BMC Cardiovascular Disorders
Ong KL, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of…
Study compares GLP-1 drug benefits and finds substantial variation in clinical effects
A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes…
Weight-loss drugs: From a trickle to a flood
It’s been varyingly called the “fat shot”, “skinny jab” or “magic pill” by politicians and celebrities who’ve put…
Prices of Ozempic vs Mounjaro vs Wegovy: How much they cost in the US, UK, India and around the world |
Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However,…
Ozempic vs Mounjaro vs Wegovy: Prices in India vs US and what the research actually shows
Ozempic, Mounjaro, Wegovy: Guide to Weight Loss Injections and Their Cost in India vs US Ozempic, Mounjaro and…
WHO reviews highlight limited long-term data on GLP-1 drug safety
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies…
Diabetes remission possible with GLP-1 drugs, Italian study confirms
Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2…
Karan Johar’s Ozempic joke: What you ought to know about weight loss drug
Ozempic 101: Is it behind Karan Johar’s weight loss? Fact sheet for health enthusiasts on benefits and risks…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
By Nancy Lapid (Reuters) -Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs should be the first medicines doctors…